Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.09.2021 | Case report

Etoposide/rituximab/ruxolitinib

No response and herpes simplex virus infection: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Meng G-Q, et al. Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection. International Immunopharmacology 96: 107606, Jul 2021. Available from: URL: http://www.elsevier.com/locate/intimp Meng G-Q, et al. Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection. International Immunopharmacology 96: 107606, Jul 2021. Available from: URL: http://​www.​elsevier.​com/​locate/​intimp
Metadaten
Titel
Etoposide/rituximab/ruxolitinib
No response and herpes simplex virus infection: case report
Publikationsdatum
01.09.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-02133-y

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Warfarin